TSE:NVLN - Novelion Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseC$13.30
Today's RangeC$13.30 - C$13.30
52-Week RangeC$10.68 - C$16.35
VolumeN/A
Average Volume3,220 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

Receive NVLN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange TSE
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolTSE:NVLN
Previous SymbolTSE:QLT
CUSIPN/A
Phone+1-604-7077000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market CapC$0.00
OptionableOptionable

Novelion Therapeutics (TSE:NVLN) Frequently Asked Questions

What is Novelion Therapeutics' stock symbol?

Novelion Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "NVLN."

Has Novelion Therapeutics been receiving favorable news coverage?

News stories about NVLN stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novelion Therapeutics earned a daily sentiment score of 1.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days.

How do I buy shares of Novelion Therapeutics?

Shares of NVLN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Novelion Therapeutics' official website?

The official website for Novelion Therapeutics is http://www.novelion.com/.

How can I contact Novelion Therapeutics?

Novelion Therapeutics' mailing address is 1800-510 Georgia St W, VANCOUVER, BC V6B 0M3, Canada. The company can be reached via phone at +1-604-7077000.


MarketBeat Community Rating for Novelion Therapeutics (TSE NVLN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  127
MarketBeat's community ratings are surveys of what our community members think about Novelion Therapeutics and other stocks. Vote "Outperform" if you believe NVLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel